Voyager Therapeutics
VYGR
70 hedge funds and large institutions have $171M invested in Voyager Therapeutics in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 7 closing their positions.
303% more call options, than puts
Call options by funds: $4.28M | Put options by funds: $1.06M
234% more capital invested
Capital invested by funds: $51.3M → $171M (+$120M)
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
19% more funds holding
Funds holding: 59 → 70 (+11)
9.28% more ownership
Funds ownership: 49.67% → 58.95% (+9.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$8.92M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.21M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.53M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$1.51M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.34M |
| 2 |
Morgan Stanley
New York
|
-$1.2M |
| 3 |
Millennium Management
New York
|
-$1.08M |
| 4 |
JP Morgan Chase
New York
|
-$734K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$644K |
VYGR Hedge Fund Activity: Q1 2022 in Review
70 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q1 2022, worth a combined $171M — up 234% from $51.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new VYGR positions and 7 closed out — a net gain of 11 holders — while 18 added to existing stakes and 19 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $8.92M. The largest seller was Acadian Asset Management, cutting an estimated $1.34M.
- 70 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2022, up from 59 in Q4 2021.
- Funds reported $171M of Voyager Therapeutics stock for Q1 2022, up 234% quarter-over-quarter.
- 18 funds opened new Voyager Therapeutics positions in Q1 2022 and 7 closed out, a net change of +11 holders.
- The largest Voyager Therapeutics buyer in Q1 2022 was Armistice Capital, an estimated $8.92M added.
- The largest Voyager Therapeutics seller in Q1 2022 was Acadian Asset Management, an estimated $1.34M sold.
Based on aggregated 13F filings for Q1 2022.